8/9 March 2022
The Swiss authority Swissmedic announced on its website that regulatory authorities around the world will work more closely together due to Covid-19. Three areas have been identified for this: research during pregnancy, medicinal products from clinical trials and monitoring of vaccines in terms of safety and efficacy.
For the second time, representatives from more than 25 countries, representing 28 drug regulatory authorities and the WHO, came together. Observational research is to be intensified by exchanging information on experiences from the development of treatments and vaccines against COVID-19. Data from observations or from clinical practice in the real world are an important complement to the information obtained from clinical trials. The current workshop identified three areas where cooperation between health authorities should be improved:
The improved cooperation should not only help during COVID-19, but also strengthen future observational research by the countries.
Here you can find the report of Swissmedic.